Published in Clin Exp Metastasis on January 01, 2003
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefes Arch Clin Exp Ophthalmol (2012) 1.42
Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev (2005) 1.41
Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer (2009) 1.23
Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res (2009) 1.19
Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem (2009) 1.18
The transcriptional repressor SNAIL is overexpressed in human colon cancer. Dig Dis Sci (2005) 1.18
Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. Cancer Res (2008) 1.18
In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res (2009) 1.08
Melanoma-restricted genes. J Transl Med (2004) 1.03
Melanoma cell adhesion molecule is a novel marker for human fetal myogenic cells and affects myoblast fusion. J Cell Sci (2006) 1.01
Slug expression during melanoma progression. Am J Pathol (2012) 0.97
IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol (2011) 0.94
Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenviron (2008) 0.92
CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One (2010) 0.92
Expression and function of bcl-2 proteins in melanoma. Curr Genomics (2008) 0.90
The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev (2014) 0.89
Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells. J Biol Chem (2009) 0.89
Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoter. Oncogene (2010) 0.84
CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res (2007) 0.83
Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. J Am Soc Nephrol (2008) 0.83
Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma. Epigenetics (2014) 0.81
Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity. Neoplasia (2010) 0.81
Stem cell factor affects tumour progression markers in metastatic melanoma cells. Clin Exp Metastasis (2006) 0.79
The transition to the metastatic phenotype of rat lymphoma cells involves up-regulation of IL-10 receptor expression and IL-10 secretion. Clin Exp Metastasis (2005) 0.76
Retinoic acid decreases ATF-2 phosphorylation and sensitizes melanoma cells to taxol-mediated growth inhibition. J Mol Signal (2008) 0.76
The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis. Oncotarget (2017) 0.75
SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. Sci Rep (2017) 0.75
Soluble TNF Regulates TACE via AP-2α Transcription Factor in Mouse Dendritic Cells. J Immunol (2016) 0.75
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 3.07
Focus on bladder cancer. Cancer Cell (2004) 2.59
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther (2003) 2.08
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol (2002) 1.96
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol (2004) 1.84
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia (2010) 1.51
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res (2003) 1.49
Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem (2005) 1.38
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res (2004) 1.33
Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem (2009) 1.32
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res (2006) 1.30
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res (2002) 1.30
Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene (2003) 1.30
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res (2002) 1.27
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem (2004) 1.24
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res (2003) 1.23
Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol (2010) 1.23
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res (2004) 1.22
Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res (2005) 1.22
Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther (2002) 1.21
Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem (2003) 1.19
Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem (2009) 1.18
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res (2006) 1.17
Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol (2008) 1.17
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res (2003) 1.17
The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res (2005) 1.16
EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther (2008) 1.13
The dicey role of Dicer: implications for RNAi therapy. Cancer Res (2010) 1.13
Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res (2005) 1.12
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res (2007) 1.11
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest (2013) 1.11
Inflammation and melanoma metastasis. Pigment Cell Melanoma Res (2009) 1.11
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res (2005) 1.11
Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. J Biol Chem (2005) 1.10
Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev (2007) 1.08
Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther (2008) 1.08
Chitosan hydrogel for localized gene silencing. Cancer Biol Ther (2011) 1.07
A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res (2003) 1.03
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther (2004) 1.03
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 1.03
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res (2008) 1.03
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol (2006) 1.02
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A (2010) 1.02
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia (2008) 1.02
Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res (2009) 1.02
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol (2008) 1.02
Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res (2006) 1.00
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol (2007) 0.99
Retracted Targeting EGFR in bladder cancer. World J Urol (2007) 0.99
Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res (2011) 0.98
ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics. Cancer (2006) 0.98
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci U S A (2007) 0.98
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res (2011) 0.98
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest (2008) 0.96
Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res (2004) 0.94
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood (2008) 0.94
ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res (2007) 0.94
Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev (2012) 0.92
CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One (2010) 0.92
Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem (2005) 0.92
Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenviron (2008) 0.92
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol (2004) 0.91
Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer (2004) 0.90
Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res (2012) 0.90
Why is melanoma so metastatic? Pigment Cell Melanoma Res (2013) 0.89
Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: modulation of genomic stability and invasion. J Cell Physiol (2005) 0.89
ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest (2013) 0.88
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget (2011) 0.87
The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res (2012) 0.86
ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells. J Biol Chem (2002) 0.86
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol (2012) 0.85
Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol (2010) 0.85
The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. Int J Cancer (2014) 0.82
A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res (2011) 0.82
Monocyte subpopulations in angiogenesis. Cancer Res (2014) 0.81
Gene expression profiling of human cutaneous melanoma: are we there yet? Cancer Biol Ther (2004) 0.78
The HOG-GLI face of melanoma. Pigment Cell Res (2007) 0.77
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol (2008) 0.77
Back to the embryonic stage: Nodal as a biomarker for breast cancer progression. Breast Cancer Res (2012) 0.76
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther (2006) 0.76
Construction and expression of intracellular anti-ATF-1 single chain Fv fragment: a modality to inhibit melanoma tumor growth and metastasis. Methods (2004) 0.76
Estela Medrano, 1943-2010. Pigment Cell Melanoma Res (2010) 0.75
Crossing the junction in the gap of melanoma brain metastasis. Pigment Cell Melanoma Res (2013) 0.75
Searching for the Achilles' heel of melanoma cells: new treatment modalities. Pigment Cell Melanoma Res (2007) 0.75